| 產(chǎn)品名稱 |
C1R-sB7 |
| 商品貨號 |
B164078 |
| Organism |
Homo sapiens, human |
| Tissue |
peripheral blood |
| Cell Type |
B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
mixed; semi-attached |
| Biosafety Level |
2 [Cells contain Herpesvirus]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
C1R-sB7 is a stable transfectant cell line established in 1988 with a modified histocompatibility complex (MHC) HLA B7 gene. It secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 was established by transfection by electroporation of the C1R cell line with a modified neomycin drug-resistant eukaryotic vector, pSP65-Neo carrying the gene for soluble B7 (sB7). It was selected in geneticin and cloned by limiting dilution.
C1R is a human B-cell lymphoblastoid line lacking surface HLA A and B antigens. C1R was derived from Hmy.2 B-LCL by gamma irradiation followed by selection for Class I monoclonal antibodies and complement. |
| Genes Expressed |
Secretes HLA B7 but does not express surface HLA B7 |
| Cellular Products |
Secretes HLA B7 but does not express surface HLA B7 |
| Comments |
C1R-sB7 secretes HLA B7 but does not express surface HLA B7.
C1R-sB7 has been a reference standard in International Workshops on soluble HLA. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Cultures can be maintained by transferring floating cells to additional flasks. Attached cells may be subcultured by scraping. Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 6,10 D13S317: 11,13 D16S539: 9,13 D5S818: 10,13 D7S820: 7,12 THO1: 8 TPOX: 8 vWA: 17 |
| Name of Depositor |
F Grumet |
| Year of Origin |
1988 |
| References |
Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
Grumet FC, et al. Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization. Hum. Immunol. 40: 228-234, 1994. PubMed: 7960967
Hiraki DD, et al. Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization. Hum. Immunol. 40: 235-246, 1994. PubMed: 7960968
Grumet FC, et al. Report of the second international soluble HLA (sHLA) workshop. Phoenix, Arizona, October 2, 1993. Hum. Immunol. 40: 153-165, 1994. PubMed: 7960956
|
